Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.

被引：1
|
作者：
Lang, I.
Inbar, M. J.
Greil, R.
Steger, G. G.
Beslija, S.
Kahan, Z.
Eniu, A. E.
Zvirbule, Z.
Sirbu, D. E.
Zielinski, C.
机构：
[1] Natl Inst Oncol, Budapest, Hungary
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] Univ Hosp Salzburg, Salzburg, Austria
[4] Med Univ Vienna, Vienna, Austria
[5] Univ Sarajevo, Inst Oncol, Clin Ctr, Sarajevo 71000, Bosnia & Herceg
[6] Univ Szeged, Szeged, Hungary
[7] Canc Inst I Chiricuta, Cluj Napoca, Romania
[8] Oncol Ctr Latvia, Riga, Latvia
[9] Med Univ Vienna, Dept Med 1, Div Clin Oncol, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1126
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [22] Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study
    Schrader, Iris
    Foerster, Frank Gerhard
    Schneeweiss, Andreas
    Geberth, Matthias
    Hahn, Lars
    Schumacher, Claudia
    Hertz-Eichenrode, Martin Michael
    Schoenegg, Winfried
    Wolfgarten, Matthias Kim
    Kutscheidt, Andreas
    Schmidt, Marcus
    Aktas, Bahriye
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION
    Kourea, H. P.
    Koutras, A. K.
    Kotoula, V.
    Bobos, M.
    Fountzila, A. Kalogera
    Papazisis, K. T.
    Christodoulou, C.
    Res, E.
    Bournakis, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 104 - 104
  • [24] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez Martin, A.
    de Ducla, S.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
  • [25] Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
    Dieras, Veronique
    Wildiers, Hans
    Jassem, Jacek
    Dirix, Luc Y.
    Guastalla, Jean-Paul
    Bono, Petri
    Hurvitz, Sara A.
    Goncalves, Anthony
    Romieu, Gilles
    Limentani, Steven A.
    Jerusalem, Guy
    Lakshmaiah, K. C.
    Roche, Henri
    Sanchez-Rovira, Pedro
    Pienkowski, Tadeusz
    Segui Palmer, Miguel Angel
    Li, Ai
    Sun, Yu-Nien
    Pickett, Cheryl A.
    Slamon, Dennis J.
    BREAST, 2015, 24 (03): : 182 - 190
  • [26] Efficacy and Safety of First-Line Bevacizumab (BEV) Combined with Paclitaxel (PAC) According to Age: Subpopulation Analysis of a Large, Multicenter, Non-Interventional Study in Patients (Pts) with HER2-Negative Metastatic Breast Cancer (MBC).
    Geberth, M.
    Foerster, F.
    Klare, P.
    Schneeweiss, A.
    Schumacher, C.
    Hahn, L.
    Tesch, H.
    Hertz-Eichenrode, M. M.
    Weinberg, R.
    Gluz, O.
    Kuemmel, S.
    Strumberg, D.
    Wuelfing, P.
    Schmidt, M.
    CANCER RESEARCH, 2009, 69 (24) : 851S - 852S
  • [27] Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).
    Lam, S. W.
    de Groot, S. M.
    Honkoop, A. H.
    Jager, A.
    ten Trje, A. J.
    Bos, M. M. E. M.
    Linn, S. C.
    van den, Bosch J.
    Nortier, J. W. R.
    Braun, J. J.
    de Graaf, H.
    Portielje, J. E. A.
    Los, M.
    Gooyer, D. D.
    van Tinteren, H.
    Boven, E.
    CANCER RESEARCH, 2011, 71
  • [28] Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
    Gligorov, Joseph
    Bines, Jose
    Alba, Emilio
    Mustacchi, Giorgio
    Cinieri, Saverio
    Gupta, Vineet
    Pierga, Jean-Yves
    Bozcuk, Hakan
    Gaafar, Rabab
    Gupta, Sudeep
    Vivanco, Guillermo Lopez
    Wang, Xiaojia
    Costa, Romulo
    Altundag, Kadri
    Chmielowska, Ewa
    de Ducla, Sabine
    Freudensprung, Ulrich
    Cortes, Paulo
    Doval, Dinesh
    CANCER RESEARCH, 2015, 75
  • [29] Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial
    Hegewisch-Becker, S.
    Lerchenmuller, C. A.
    Welt, A.
    Decker, T.
    Just, M.
    Steffens, C.
    Hipper, A.
    Marschner, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345